StockNews.com Initiates Coverage on Agile Therapeutics (NASDAQ:AGRX)

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRXGet Rating) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Several other brokerages also recently issued reports on AGRX. Zacks Investment Research upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Maxim Group cut Agile Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, April 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Agile Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $135.30.

Shares of NASDAQ AGRX opened at $2.03 on Thursday. The business’s 50-day moving average price is $10.62 and its two-hundred day moving average price is $17.80. Agile Therapeutics has a one year low of $1.82 and a one year high of $69.60. The company has a market capitalization of $6.83 million, a P/E ratio of -0.07 and a beta of 1.57.

Agile Therapeutics (NASDAQ:AGRXGet Rating) last announced its earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($8.00) earnings per share for the quarter, missing the consensus estimate of ($6.80) by ($1.20). Agile Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 376.29%. The business had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.58 million. During the same quarter in the previous year, the company earned ($8.00) EPS. On average, equities research analysts forecast that Agile Therapeutics will post -14.8 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its holdings in Agile Therapeutics by 33.8% during the fourth quarter. Perceptive Advisors LLC now owns 21,294,485 shares of the specialty pharmaceutical company’s stock worth $10,394,000 after acquiring an additional 5,374,560 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in Agile Therapeutics by 571.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,161,006 shares of the specialty pharmaceutical company’s stock worth $1,055,000 after buying an additional 1,839,143 shares during the last quarter. BlackRock Inc. increased its position in Agile Therapeutics by 2.5% during the fourth quarter. BlackRock Inc. now owns 1,507,654 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 37,394 shares during the last quarter. Morgan Stanley increased its position in Agile Therapeutics by 3,348.3% during the second quarter. Morgan Stanley now owns 769,445 shares of the specialty pharmaceutical company’s stock worth $1,023,000 after buying an additional 747,131 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Agile Therapeutics by 25.1% during the fourth quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company’s stock worth $358,000 after buying an additional 147,194 shares during the last quarter. Institutional investors and hedge funds own 27.96% of the company’s stock.

Agile Therapeutics Company Profile (Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Recommended Stories

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.